Suzhou Gracell Biotechnologies Co., Ltd.
Suzhou Gracell Biotechnologies Co., Ltd.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT06530849 | |
| Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 1 | 2026-07-23 | NCT07250269 |